Skip to main content
SpringerLink
Log in
Book cover

Cancer Immunology: Innovative Approaches to Therapy pp 29–67Cite as

Tumor specific antigens induced by mutagens and DNA hypomethylating agents: implications for the immunobiology of neoplasia

  • Chapter

  • 56 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 27))

Abstract

The effusive enthusiasm that characterized so much of tumor immunology research during the 1960’s and 1970’s has gradually given way to a widespread and pervasive cynicism. One could cite many reasons for this but three in particular stand out. First, the incidence of almost all types of cancer in immunodeficient humans or animals (such as athymic nude mice) appears no greater than in appropriate control groups [1, 2]. This stands in sharp contrast to what one would have predicted on the basis of immune surveillance theories of cancer. Second, clinical trials involving immunotherapy have generally provided discouragingly negative results in terms of long-term patients survival or cures. Third, the entire theoretical foundation of tumor immunology itself — the existence of strictly tumor specific antigens — has yet to be definitively proven in human neoplasia despite over 25 years of intensive world-wide efforts to unequivocally uncover their presence.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moller, G., Moller, E. 1976. The concept of immunological surveillance against neoplasia. Transplant. Rev. 28:3–15.

    PubMed  CAS  Google Scholar 

  2. Stutman, O. 1975. Immunodepression and malignancy. Adv. Cancer Res. 22:261–422.

    PubMed  CAS  Google Scholar 

  3. Foley, E.J. 1953. Antigenic properties of methylclolanthrene-induced tumours in mice of the strain of origin. Cancer Res. 13:35–37.

    Google Scholar 

  4. Prehn, R.T., Main, J.M. 1957. Immunity to methylcholanthrene-induced sacromas. J. Natl. Cancer Inst. 18:759–778.

    Google Scholar 

  5. Klein, G., Sjogren, H., Klein, E., Hellstrom, K. 1960. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20:1561–1572.

    PubMed  CAS  Google Scholar 

  6. Hewitt, H.B., Blake, E.R., Walder, A.S. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33:241–259.

    PubMed  CAS  Google Scholar 

  7. Baldwin, R.W., Embleton, M.J. 1969. Immunology of spontaneously arising rat mammary adenocarcinomas. Int. J. Cancer 4:430–439.

    PubMed  CAS  Google Scholar 

  8. Embleton, M.J., Middle, J.G. 1981. Immune responses to naturally occurring rat sarcomas. Br. J. Cancer 43:44–52.

    PubMed  CAS  Google Scholar 

  9. Hewitt, H.B. 1978. The choice of animal tumors for experimental studies of cancer therapy. Adv. in Cancer Res. 27:149–200.

    CAS  Google Scholar 

  10. Hewitt, H.B. 1981. Immunotherapy of cancer: an underview. Modern Medicine of Canada 35:1355–1361.

    Google Scholar 

  11. Hewitt, H.B. 1982. Animal tumor models and their relevance to human tumor immunology. J. of Biol. Resp. Modifiers 1:107–119.

    Google Scholar 

  12. Hewitt, H.B. 1979. A critical examination of the foundations of immunotherapy for cancer. Clin. Radiol. 30:361–369.

    PubMed  CAS  Google Scholar 

  13. Hilgers, J., Haverman, J., Nusse, R., van Bliterswijk, W.J., Cleton, F.J., Hageman, Ph.C., van Nie, R., Calafat, J. 1975. Immunologic, virologic, and genetic aspects of mammary tumor virus-induced cell-surface antigens: presence of these antigens and the Thy 1.2 antigen on murine mammary gland and tumor cells. J. Natl. Cancer Inst. 54:1323–1333.

    PubMed  CAS  Google Scholar 

  14. Nowinski, R.C., Klein, P.A. 1975. Anomalous reactions of mouse alloantisera with cultured tumor cells. IV. Cytotoxicity is caused by antibodies to leukemia viruses. J. Immunol. 115:1261–1268.

    PubMed  CAS  Google Scholar 

  15. McGarrity, G.J., Vanaman, V., Sarama, J. 1984. Cytogenetic effects of mycoplasmal infection of cell cultures: a review. In Vitro 20:1–18.

    PubMed  CAS  Google Scholar 

  16. Hamburger, R.N., Pious, D.A., Mills, S.E. 1963. Antigenic specificities acquired from the growth medium by cells in tissue culture. Immunology 6:439–449.

    PubMed  CAS  Google Scholar 

  17. Sulit, H.L., Golub, S.H., Irie, R.F., Gupta, R.K., Grooms, G.A., Morton, D.L. 1976. Human tumor cells grown in fetal calf serum and human serum: influences on the tests for lymphocyte cytotoxicity, serum blocking and serum arming effects. Int. J. Cancer 17:461–468.

    PubMed  CAS  Google Scholar 

  18. Cairns, J., Logan, J. 1983. Step by step into carcinogenesis. Nature 18:582–583.

    Google Scholar 

  19. Lake, P., Mitchinson, N.A. 1977. Regulatory mechanisms in the immune response to cell-surface antigens. Cold Spring Harbour Symp. Quant. Biol. 41:589–595.

    Google Scholar 

  20. Lake, P., Mitchinson, N.A. 1976. Associative control of the immune response to cell surface antigens. Immunological Communications 5:795–805.

    PubMed  CAS  Google Scholar 

  21. Shen, F.W., Hwang, S.M., Boyse, E.A. 1978. Adoptive immunization in the production of Lyt and other alloantisera. Immunogenetics 6:389–395.

    Google Scholar 

  22. Kobayashi, H. 1979. Viral xenogenization of intact tumor cells. Adv. in Cancer Res. 30:279–297.

    CAS  Google Scholar 

  23. Martin, W.J., Wunderlich, J.R., Fletcher, F., Inman, J.K. 1971. Enhanced immunogenicity of chemically-coated syngeneic tumor cells. Proc. Natl. Acad. Sci. USA 68:469–471.

    PubMed  CAS  Google Scholar 

  24. Toffaletti, D.L., Darrow, T.L., Scott, D.W. 1983. Augmentation of sungeneic tumor-specific immunity by semiallogeneic cell hybrids. J. of Immunol. 130:2982–2986.

    CAS  Google Scholar 

  25. Kawashima, K., Nagura, E., Watanabe, E., Mizoguchi, K., Saga, S., Isobe, K., Nakashima, I., Yamada, K., Oikawa, T., Kojima, K. 1983. High-grade tumor-specific immunity induced by L1210 leukemia variants obtained from the culture of L1210 cells fused with Lesch-nyhan fibroblasts. Int. J. Cancer 32:507–514.

    PubMed  CAS  Google Scholar 

  26. Yefenof, E., Goldapfel, M., Ber, R. 1982. Nonimmunogenic radiation-induced lymphoma: immunity induction by a somatic cell hybrid. J. Natl. Cancer Inst. 68:841–849.

    PubMed  CAS  Google Scholar 

  27. O’Donnell, R.W., Horan, P.K., Minken, T.J., Chuang, C., Henshaw, E.C., McCune, C.S. 1984. Antitumor immunity induced by hybrid tumor cells: comparison between hybrids and parental tumor. Cancer Res. 44:487–492.

    PubMed  Google Scholar 

  28. Kerbel, R.S., Frost, P. 1982. Heritable alterations in tumor-cell immunogenicty. Immunology Today 3:34–35.

    Google Scholar 

  29. Frost, P., Kerbel, R.S. 1983. On a possible epigenetic mechanism(s) of tumor cell heterogeneity. Cancer Metastasis Reviews 2:375–378.

    PubMed  CAS  Google Scholar 

  30. Kobayashi, H., Sendo, F., Kaji, H., Shirai, T., Saito, H., Takeichi, N., Hosokawa, M., Kodama, T. 1970. Inhibition of transplanted rat tumors by immunization with identical tumor cells infected with Friend virus. J. Natl. Cancer Inst. 44:11–19.

    PubMed  CAS  Google Scholar 

  31. Kenne, J.A., Foreman, J. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768–782.

    Google Scholar 

  32. Bonmassar, E., Bonmassar, A., Vadlamudi, S., Goldin, A. 1970. Immunological alteration of leukemia cells in vivo after treatment with an antitumor drug. Proc. Natl. Acad. Sci. 66:1089–1095.

    PubMed  CAS  Google Scholar 

  33. Nicolin, A., Bini, A., Coronetti, E. 1974. Cellular immune response to a drug-treated L5178Y lymphoma subline. Nature 251:654–655.

    PubMed  CAS  Google Scholar 

  34. Bonmassar, A., Frait, L., Fioretti, M.C., Ramani, L., Giampietri, A., Goldin, A. 1979. Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5 (3,3dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC). Europ. J. Cancer 15:933–939.

    CAS  Google Scholar 

  35. Giampietri, A., Bonmassar, A., Puccetti, P., Circolo, A., Goldin, A., Bonmassar, E. 1981. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Cancer Res. 41:681–687.

    PubMed  CAS  Google Scholar 

  36. Campanile, F., Houchens, D.P., Gaston, M., Goldin, A., Bonmassar, E. 1975. Brief communication: increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice. J. Natl. Cancer Inst. 55:207–209.

    PubMed  CAS  Google Scholar 

  37. Bonmassar, E., Testorelli, C., Franco, P., Goldin, A., Cudkowicz, G. 1975. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs. Cancer Res. 35: 1957–1962.

    PubMed  CAS  Google Scholar 

  38. Taramelli, D., Romani, L., Bonmassar, A., Goldin, A., Fioretti, M.C. 1981. Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3’-dimethyl1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo. Europ. J. Cancer 17:411–420.

    CAS  Google Scholar 

  39. Romani, L., Fioretti, M.C., Bonmassar, E. 1979, In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3’-dimethyl-l-triazeno)-imidazole-4-carboxamide in vivo. Transplantation 28:218–222.

    PubMed  CAS  Google Scholar 

  40. Nicolin, A., Veronese, F., Marelli, O., Goldin, A. 1980. Immunological resistance to L1210 leukemia induced by viable L1210/DTIC cells. Cancer Immunol. Immunother. 9:43–48.

    Google Scholar 

  41. Bonmassar, E., Bonmassar, A., Vadlamudi, S., Goldin, A. 1972. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide. Cancer Res. 32:1446–1450.

    PubMed  CAS  Google Scholar 

  42. Fioretti, M.C., Bianchi, R., Romani, L., Bonmassar, E. 1983. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. J. Natl. Cancer Inst. 71:1247–1251.

    PubMed  CAS  Google Scholar 

  43. Giampietri, A., Fioretti, M.C., Goldin, A., Bonmassar, E. 1980. Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J. Natl. Cancer Inst. 64:297–301.

    PubMed  CAS  Google Scholar 

  44. Contessa, A.R., Giammietri, A., Bonmassar, A., Goldin, A. 1979. Increased immunogenicity of L1210 leukemia following short-term exposure to 5(3,3’-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC) in vivo or in vitro. Cancer Immunol. Immunother. 7:71–76.

    CAS  Google Scholar 

  45. Contessa, A.R., Bonmassar, A., Giampietri, A., Circolo, A., Goldin, A., Fioretti, M.C. 1981. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3’-dimethyl-l-triazeno)imicazole-4-carboxamide. Cancer Res. 41:2476–2482.

    PubMed  CAS  Google Scholar 

  46. Mihich, E. 1969. Modification of tumor regression by immunologic means. Cancer Res. 29:2345–2350.

    PubMed  CAS  Google Scholar 

  47. Fuji, H., Mihich, E. 1975. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstated by plaque assay. Cancer Res. 35:946–952.

    PubMed  CAS  Google Scholar 

  48. Fuji, H., Mihich, E., Pressman, D. 1977. Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro. J. Immunol. 3:983–986.

    Google Scholar 

  49. Scmid, F.A., Hutchison, D.J. 1973. Decrease in oncogenic potential of L1210 leukemia by triazenes. Cancer Res. 33:2161–2165.

    Google Scholar 

  50. Tsukagoshi, S., Hashimoto, Y. 1973. Increased immunosensitivity in nitrogen mustard-resistant Yoshida sarcoma. Cancer Res. 33: 1038–1042.

    PubMed  CAS  Google Scholar 

  51. Boon, T. 1983. Antigenic tumor cell variants obtained with mutagens. Adv. Cancer Res. 39:121–151.

    PubMed  CAS  Google Scholar 

  52. Mondai, S., Embleton, M.J., Marquardt, H., Heidelberger, C. 1971. Production of variants of decreased malignancy and antigenicity from clones transformed in vitro by methylcholanthrene. Int. J. Cancer 8:410–420.

    Google Scholar 

  53. Van Pel, A., Georlette, M., Boon, T. 1979. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Proc. Natl. Acad. Sci. USA 76:5282–5285.

    PubMed  Google Scholar 

  54. Boon, T., Kellerman, O. 1977. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma line. Proc. Natl. Acad. Sci. USA 74:272–275.

    PubMed  CAS  Google Scholar 

  55. Uyttenhove, C., Van Snick, J., Boon, T. 1980. Immunogenic variants obtained by muta-genesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp. Med. 152:1175–1183.

    PubMed  CAS  Google Scholar 

  56. Van Pel, A., Boon, T. 1982. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl. Acad. Sci. USA 79:4718–4722.

    PubMed  Google Scholar 

  57. Van Pel, A., Vessiere, F., Boon, T. 1983. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J. Exp. Med. 157: 1992–2001.

    PubMed  Google Scholar 

  58. Boon, T., Van Pel, A. 1978. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. USA 75:1519–1523.

    PubMed  CAS  Google Scholar 

  59. Boon, T., Van Snick, J., Van Pel, A., Uyttenhove, C., Marchand, M. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152:1184–1193.

    PubMed  CAS  Google Scholar 

  60. Maryanski, J.L., Van Snick, J., Cerottini, J.-C., Boon, T. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur. J. Immunol. 12:401–406.

    PubMed  CAS  Google Scholar 

  61. Maryanaski, J.L., Marchand, M., Uyttenhove, C., Boon, T. 1983. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Int. J. Cancer 31:119–123.

    Google Scholar 

  62. Maryanski, J.L., Boon, T. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Eur. J. Immunol. 12:406–412.

    PubMed  CAS  Google Scholar 

  63. Georlette, M., Boon, T. 1981. Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor. Eur. J. Cancer Clin. Oncol. 17:1083–1087.

    PubMed  CAS  Google Scholar 

  64. Frost, P., Kerbel, R.S., Bauer, E., Tartamella-Biondo, R., Cefalu, W. 1983. Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res. 43:125–132.

    PubMed  CAS  Google Scholar 

  65. Carlow, D.A., Kerbel, R.S., Feltis, J.T., Elliott, B.E. 1985. Enhanced expression of class I MHC (DK) gene products on immunogenic variants of a spontaneous murine carcinoma. J. Natl. Cancer Inst. 75:291–301.

    PubMed  CAS  Google Scholar 

  66. Zbar, B., Sukumar, S., Tanio, Y., Terata, N., Hovis, J. 1984. Antigenic variants isolated froma mutagen-treated Guinea pig fibrosarcoma. Cancer Res. 44:5079–5085.

    PubMed  CAS  Google Scholar 

  67. Peppoloni, S., Herberman, R., Gorelik, E. 1984. Induction of highly immunogenic variants of 3LL tumor by UV irradiation.

    Google Scholar 

  68. Kerbel, R.S. 1979. Immunologic studies of membrane mutants of a highly metastaic murine tumor. Am. J. Pathol. 97:609–622.

    PubMed  CAS  Google Scholar 

  69. Larizza, L., Schirrmacher, V., Stohr, M., Pfluger, E., Dzarlieva, R. 1984. inheritance of immunogenicity and metastatic potential in murine cell hybrids from the T-lymphoma ESb08 and normal spleen lymphocytes. J. Natl. Cancer Inst. 72: 1371–1381.

    PubMed  CAS  Google Scholar 

  70. Frost, P., Liteplo, R.G., Donaghue, T.P., Kerbel, R.S. 1984. Selection of strongly immu ogenic “tum- ” variants from tumors at high frequency using 5-azacytidine. J. Exp. Med. 159:1491–1501.

    PubMed  CAS  Google Scholar 

  71. Marchand, M., Caspar, P., Boon, T. 1983. Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. Eur. J. Cancer Clin. Oncol. 19:1529–1537.

    PubMed  CAS  Google Scholar 

  72. Schmike, R.T. 1984. Gene amplification, drug resistance, and cancer. Cancer Res. 44:1735–1742.

    Google Scholar 

  73. Jones, P.A., Taylor, S.M. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85–93.

    PubMed  CAS  Google Scholar 

  74. Landolph, J.R., Jones, P.A. 1982. Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T1/2 clone 8 and V79 cells. Cancer Res. 42:817–823.

    PubMed  CAS  Google Scholar 

  75. Bouck, N., Kokkinakis, D., Ostrowsky, J. 1984. Induction of a step in carcinogenesis that is normally associated with mutagenesis by nonmutagenic concentrations of 5-azacytidine. Molec. & Cell. Biol. 4:1231–1237.

    CAS  Google Scholar 

  76. Harris, M. 1982. Induction of thymidine kinase in enzyme-deficient Chinese hamster cells. Cell 29:483–492.

    PubMed  CAS  Google Scholar 

  77. Gasson, J.C., Ryden, T., Bourgeois, S. 1983. Role of de novo DNA methylation in the glucocorticoid resistance of a T-lymphoid cell line. Nature 302:621–623.

    PubMed  CAS  Google Scholar 

  78. Tennant, R.W., Otten, J.A., Myer, F.E., Rascati, R.J. 1982. Induction of retrovirus gene expression in mouse cells by some chemical mutagens. Cancer Res. 42:3050–3055.

    PubMed  CAS  Google Scholar 

  79. Worton, R.G., Grant, S.G., Duff, C. 1984. In: Gene Transfer and Cancer (Pearson, M.L., Sternberg, N.L., eds.) Raven Press, N.Y. pp. 265–272.

    Google Scholar 

  80. Kerbel, R.S., Frost, P. Liteplo, R., Carlow, D.A., Elliott, B.E. 1984. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J. Cell. Physiol. Suppl. 3:87–97.

    PubMed  CAS  Google Scholar 

  81. Razin, A.D., Riggs, A.D. 1980. DNA methylation and gene function. Science 70:604–610.

    Google Scholar 

  82. Riggs, A.D., Jones, P.A. 1983. 5-methyl-cytosine gene regulation, and cancer. Adv. Cancer Res. 40:1–30.

    PubMed  CAS  Google Scholar 

  83. Ehrlich, M., Wang, R.V.H. 1981. 5-methyl-cytosine eukaryotic DNA. Science 212: 1350–1357.

    PubMed  CAS  Google Scholar 

  84. Doerfler, W. 1983. DNA methylation and gene activity. Ann. Rev. Bioch. 52:93–124.

    CAS  Google Scholar 

  85. Razin, A., Szyf, M. 1984. DNA methylation patterns: formation and function. Biochemica & Biophysica Acta 782:331–342.

    CAS  Google Scholar 

  86. Harrison, J.J., Anisowicz, A., Gadi, I.K., Raffeld, M., Sager, R. 1983. Azacytidine-induced tumorigenesis of CHEF/18 cells: correlated DNA methylation and chromosome changes. Proc. Natl. Acad. Sci. USA 80:6606–6610.

    PubMed  CAS  Google Scholar 

  87. Trainer, D., Kline, T., Mallon, F., Greig, R., Poste, G. 1984. The effect of agents altering DNA methylation on the organ colonization and metastatic behavior of B16 melanoma cells. Cancer Res. - submitted.

    Google Scholar 

  88. Olsson, L., Forchhammer, J. 1984. Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity. Proc. Natl. Acad. Sci. USA 81:3389–3393.

    PubMed  CAS  Google Scholar 

  89. Walker, C., Ranney, D.F., Shay, J.W. 1984. 5-azacytidine-induced uncoupling of differentiation and tumorigenicity in a murine cell line. J. Natl. Cancer Inst. 73:877–885.

    PubMed  CAS  Google Scholar 

  90. Weissman, B.E., Stanbridge, E.J. 1983. Complementation of the tumorigenic phenotype in human cell hybrids. J. Natl. Cancer Inst. 70:667–672.

    PubMed  CAS  Google Scholar 

  91. Robertson, M. 1983. Oncogenes and mutistep carcinogenesis. Brit. Med. J. 287:1084–1086.

    CAS  Google Scholar 

  92. Kerbel, R.S., Dennis, J., Lagarde, A., Frost, P. 1982. Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants. Cancer Metastasis Rev. 1:99–140.

    PubMed  CAS  Google Scholar 

  93. Hanna, N., Schneider, M. 1983. Enhancement of tumor metastasis and suppression of natural killer cell activity by ß-estradiol treatment. J. Immunol. 130:974–980.

    PubMed  CAS  Google Scholar 

  94. Haliotis, T., Dexter, D., and Roder, J.C. 1985. Low resistance to spontaneously arising tumors in natural killer cell deficient beige mutant mice. J. Natl. Cancer Inst. - in press.

    Google Scholar 

  95. Urban, J.L., Schreiber, H. 1983. Selection of macrophage-resistant progressor tumor variants by the normal host: requirement for concomitant T cell-mediated immunity. J. Exp. Med. 157:642–656.

    PubMed  CAS  Google Scholar 

  96. Koprowski, H., Herlyn, D., Lubeck, M., Defrertas, E., Sears, H.F. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc. Natl. Acad. Sci. USA 81:216–219.

    Google Scholar 

  97. Chow, D.A. 1984. Tumor selection in vivo for reduced sensitivity to natural resistance and natural antibodies. J. Natl. Cancer Inst. 72:339–346.

    PubMed  CAS  Google Scholar 

  98. Chow, D.A. 1984. Variant generation and selection: an in vitro model of tumor progression. Int. J. Cancer 33:541–545.

    PubMed  CAS  Google Scholar 

  99. Ahrland-Richter, L., Klein, E., Merino, F. 1982. Role of H-2 antigens in the host response against methylcholanthrene induced tumors. Immunogenetics 15:53–62.

    Google Scholar 

  100. Kripkie, M.L. 1981. Immunologic mechanisms in UV radiation carcinogenesis. Adv. Cancer Res. 34:69–106.

    Google Scholar 

  101. Brunner, K.T., Weiss, A., MacDonald, H.R., Cerottini, J.-C. 1982. Cytolytic T lymphocyte clones recognizing murine sarcoma virus induced tumor antigens. In: Isolation, Characterization and Utilization of T Lymphocyte Clones (Fathman, C., Fitch, F., eds.) Academic Press, N.Y. pp. 298–313.

    Google Scholar 

  102. Gidlund, M., Orn, A., Wigzell, H., Senik, A., Gresser, I. 1978. Enhanced NK cell activity in mice injected with interferon inducers. Nature 273:759–761.

    PubMed  CAS  Google Scholar 

  103. Nagy, Z.A., Baxevanis, C.N., Ishii, N., Klein, J. 1981. Ia antigens as restriction molecules in Ir-gene controlled T cell proliferation. Immunol. Rev. 60:59–83.

    PubMed  CAS  Google Scholar 

  104. North, R.J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 55:1063–1074.

    Google Scholar 

  105. Dennis, J.W., Laferté, S., Man, M.S., Elliott, B.E., Kerbel, R.S. 1984. Adoptive immune therapy in mice bearing poorly immunogenic metastases using T lymphocytes stimulated against highly immunogenic mutant sublines. Int. J. Cancer - 34:709–716.

    PubMed  CAS  Google Scholar 

  106. Rosenberg, S.A. 1982. Potential use of expanded T lymphoid-cells and T cell clones for the immunotherapy of cancer. In: Isolation, Characterization and Utilization of T Lymphocyte Clones (Fathman, G.G., Fitch, F.W. eds.) Academic Press, N.Y. pp. 453–494.

    Google Scholar 

  107. Fujiwara, H., Fukuzawa, M., Yoshioka, T., Nakajima, H., Hamaska, T. 1984. The role of tumor specific Lyt-1+ 2- T cells in eradicating tumor cells in vivo. J. Immunol. 133: 1671–1676.

    PubMed  CAS  Google Scholar 

  108. Kelso, A., MacDonald, H.R. 1982. Precursor frequency analysis of lymphokine-secreting alloreactive T lymphocytes. Dissociation of subsets producing interleukin-2, macrophage activating factor, and granulocyte-macrophage colony stimulating factor on the basis of Lyt-2 phenotype. J. Exp. Med. 156: 1366–1379.

    PubMed  CAS  Google Scholar 

  109. Krammer, P.H., Marcucci, F., Waller, M., Kirchner, H. 1982. Heterogeneity of soluble T cell products. I. Frequency and correlation analysis of cytotoxic and immune interferon (IFN-y) producing spleen cells in mouse. Eur. J. Immunol. 12:200–204.

    PubMed  CAS  Google Scholar 

  110. Rosenstein, M., Rosenberg, S.A. 1984, Generation of lytic and proliferative lymphoid clones to syngeneic tumors: in vitro and in vivo studies. J. Natl. Cancer Inst. 72:1161–1165.

    PubMed  CAS  Google Scholar 

  111. Klein, J., Baxevanis, C., Nagy, Z. 1981. The traditional and a new version of the mouse H-2 complex. Nature 291:455–460.

    PubMed  CAS  Google Scholar 

  112. VanSnick, J., Maryanski, J., Van Pel, A., Parmiani, G., Boon, T. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. Europ. J. Immunol. 12:905–908.

    CAS  Google Scholar 

  113. Pilarski, L., Vergidis, D. 1982. Cytotoxic T cell response to minor histocompatibility antigens: apparent lack of H-2 reduction in killers stimulated by membrane fragments. J. Exp. Med. 156:217–229.

    PubMed  CAS  Google Scholar 

  114. Doherty, P.C., Korngold, R., Schwartz, D.H., Bennick, J R. 1981. Development and loss of virus specific thymic competence in bone marrow radiation chimeras and normal mice. Immunol. Rev. 58:37–72.

    PubMed  CAS  Google Scholar 

  115. Bernards, R., Schrier, P.I., Houwelling, A., Bos, J.L., vander Eb, A.J., Lelief, C.J.M. 1983. Tumorigenicity of cells transformed by adenovirus type 2 by evasion of T cell immunity. Nature 305:776–779.

    PubMed  CAS  Google Scholar 

  116. Binz, H., Fenner, M., Frei, D., Wigzell, H. 1983. Two independent receptors allow sensitive target lysis by T cell clones. J. Exp. Med. 157:1252–1260.

    PubMed  CAS  Google Scholar 

  117. Natali, P.G., Cavaliere, R., Bigotti, A, Nicotra, M.R., Russo, C. et al. 1983. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J. Immunol. 130:1462–1466.

    PubMed  CAS  Google Scholar 

  118. Nowell, P.C. 1976. The clonal evolution of tumor cell populations. Science 194:23–28.

    PubMed  CAS  Google Scholar 

  119. Natali, P.G., Giacomini, P., Bigotti, A., Imai, K., Nicotra, M.R., Ng, A.K., Ferrone, S. 1983. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res. 43:660–668.

    PubMed  CAS  Google Scholar 

  120. Whitwell, H.L., Hughes, H.P.A., Moore, M., Ahmed, A. 1984. Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease. Br. J. Cancer 49:161–172.

    PubMed  CAS  Google Scholar 

  121. Rowe, D.J., Beverley, P. 1984. Characterization of breast cancer infiltrates using monoclonal antibodies to human leucocyte antigens. Br. J. Cancer 49:161–172.

    Google Scholar 

  122. Fleming, K.A., McMichael, A., Morton, J.A., Wood, J., McGee, J.D. 1981. Distribution of HLA class I antigens in normal human tissue and in mammary carcinoma. J. Clin. Path. 34:779–784.

    PubMed  CAS  Google Scholar 

  123. Weiss, M.A., Michael, J.G., Resce, A.J., Dipersio, L. 1981. Heterogeneity of ß-2-microglobulin in human breast carcinoma. Lab. Invest. 45:46–57.

    PubMed  CAS  Google Scholar 

  124. Gatter, K.C., Abdulaziz, Z., Beverley, P. et al. 1982. Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J. Clin. Path. 35:1253–1267.

    PubMed  CAS  Google Scholar 

  125. Turbitt, M.L., Mackie, R.M. 1981. Loss of ß-2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Am. J. Derm. 104:507–513.

    CAS  Google Scholar 

  126. Holden, C.A., Sanderson, A.R., MacDonald, D.M. 1983. Absence of human leukocyte antigen molecules in skin tumors and some cutaneous appendages. J. Am. Acad. Derm. 9:867–871.

    PubMed  CAS  Google Scholar 

  127. Natali, P.G., Viora, M., Nictoin, M.R. et al. 1983. Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor associated antigens and histocompatibility antigens. J. Natl. Cancer Inst. 71:439–447.

    PubMed  CAS  Google Scholar 

  128. Natali, P.G., ReMartino, C., Quaranta, V., Bigotti, A., Pellegrino, M.A., Ferrone, S. 1981. Changes in Ia-like antigen expression on malignant cells. Immunogenetics 12:409–413.

    PubMed  CAS  Google Scholar 

  129. Sanderson, A.R., Beverley, P.C.L. 1983. Interferon, 13–2 microglobulin, and immunoselection in the pathway to malignancy. Immunology Today 4:211–213.

    CAS  Google Scholar 

  130. VanPel, A., Georlette, M., Boon, T. 1979. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Proc. Natl. Sci. 76:5282–5285.

    CAS  Google Scholar 

  131. Maryanski, J.L., Szpirer, C., Boon, T. 1983. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9:345–357.

    PubMed  CAS  Google Scholar 

  132. Worzel, R.D., Phillips, C., Schreiber, H. 1983. Multiple tumor specific antigens expressed on a single tumour cell. Nature 304:165–167.

    Google Scholar 

  133. Horton, M., O’Brien, H., Takei, F. 1981. Isolation and characterization of regulatory variants for the expression of Ly-6 gene complex antigens. In: Mechanisms of Lymphocyte Activation (Resch, K., Kirchner, H. eds.) Elsevier, North Holland. pp. 260–263.

    Google Scholar 

  134. Mukherji, B., MacAlister, T. 1983. Clonal analysis of cytotoxic T cell response against human melanoma. J. Exp. med. 158:240–245.

    PubMed  CAS  Google Scholar 

  135. Bailey, D.W. 1982. How pure are inbred strains of mice? Immunology Today 3:210–214.

    Google Scholar 

  136. Dakuabus, T., Ahrlund-Richter, L., Merino, F., Klein, E., Klein, G. 1981. Reduced humoral and cellular cytotoxic sensitivity in major histocompatibility variants of the YAC lymphoma. Immunogenetics 12:371–380.

    Google Scholar 

  137. Rosloniec, E.F., Kuhn, M.H., Genyea, C.A., Reed, A.H., Jennings, J.J. et al. 1984. Aggressiveness of SJL/J lymphomas correlates with absence of H-2D antigens. J. Immunol. 132:945–952.

    PubMed  CAS  Google Scholar 

  138. Meruelo, D. 1979. A role for elevated H-2 antigen expression in resistance to neoplasia caused by radiation-induced leukemia virus. J. Exp. Med. 149:898–909.

    PubMed  CAS  Google Scholar 

  139. Plata, F., Tilkin, A.-F., Levy, J.-P., Lilly, F. 1981. Quantitative variations in the expression of H-2 antigens on murine leukemia virus-induced tumor cells can affect pattern of H-2 restricted tumor specific CTL. J. Exp. Med. 154:1795–1810.

    PubMed  CAS  Google Scholar 

  140. Festenstein, H., Schmidt, W., 1981. Variation in MHC antigenic profiles of tumor cells and its biological effects. Immunol. Rev. 60:85–127.

    PubMed  CAS  Google Scholar 

  141. Codington, J.F., Das, H.R., Dalianis, T., Klein, G., Miller, S.C., Silber, C et al. 1983. Cell surface characteristics of an allotransplantable TA3 ascites subline resulting from a process of immunoselection. Cancer Res. 43:4373–4381.

    PubMed  CAS  Google Scholar 

  142. Maher, L.J., Dove, W.F. 1984. Overt expression of H-2 serotypes on EC cells is not necessary for host rejection. Immunogenetics 19:343–347.

    PubMed  Google Scholar 

  143. Schatman, M.L., Ostrand-Rosenberg, S. 1984. H-2 antigen induction and cessation of DNA synthesis in a murine teratocarcinoma are requisite for tumor rejection. Fed. Proc. 42: Abstract # 1212, p. 1624.

    Google Scholar 

  144. Gooding, L.R. 1982. Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV40 virus. Immunoresistance in vivo correlates with phenotypic loss of H-2KK. J. Immunol. 129:1306–1312.

    PubMed  CAS  Google Scholar 

  145. Haywood, G.R., McKhann, C.F. 1971. Antigenic specificities of murine sarcomas. Reciprocal relationship between H-2 antigen and tumor specific immunogenicity. J. Exp. Med. 133:1171–1187.

    PubMed  CAS  Google Scholar 

  146. Brickell, P.M., Latchman, D.S., Murphy, D., Willison, K., Rigby, P.W.J. 1983. Activation of a Qa/T1a class I major histocompatibility antigen gene is a general feature of oncogenesis. Nature 306:756–760.

    PubMed  CAS  Google Scholar 

  147. Klein, J. 1975. Biology of the Mouse Histocompatibility Complex. Springer Verlag, N.Y. pp. 45–81.

    Google Scholar 

  148. Holtkamp, B., Fischer Lindahl, K., Segall, M., Rajewsky, K. 1979. Spontaneous loss and subsequent stimulation of H-2 expression in clones of a heterozygous lymphoma line. Immunogenetics 9:405–421.

    Google Scholar 

  149. Cowing, C., Chapdelaine, J.M. 1983. T cells discriminate between la antigens expressed on allogeneic accessory cells and B cells: A potential function for carbohydrate side chains on Ia molecules. Proc. Natl. Acad. Sci USA 80:6000–6004.

    PubMed  CAS  Google Scholar 

  150. Berent, M., North, R. 1980. T cell mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151:69–80.

    Google Scholar 

  151. Pilarski, L.M. 1977. A requirement for antigen-specific helper T cells in the generation of cytoxic T cells from thymocyte precursors. J. Exp. Med. 145:709–725.

    PubMed  CAS  Google Scholar 

  152. Rosenthal, A., Wright, S., Cedar, H., Flavell, R., Grosveld, F. 1984. Regulated expression of an introduced MHC H-2KK gene in murine embryonal carcinoma cells. Nature 310:415–418.

    PubMed  CAS  Google Scholar 

  153. Rao, A., Faas, S.J., Cantor, H. 1984. Activation specificity of arsonate-reactive T cell clones. Structural requirement for hapten recognition and comparison with monoclonal antibodies. J. Exp. Med. 159:479–494.

    PubMed  CAS  Google Scholar 

  154. Gramkouski, S.H., Heagy, W., Sanchez-Madrid, F., Springer, T.A., Martz, E. 1983. Blocking of CTL-mediated killing by monoclonal antibodies to LFA-1 and LYT-2,3. I. Increased susceptibility to blocking after papain treatment of target cells. J. Immunol. 130:25462451.

    Google Scholar 

  155. Herrmann, S.H., Mescher, M.F. 1981. Secondary cytolytic T lymphocyte stimulation by purified H-2KK in liposomes. Proc. Natl. Acad. Sci. USA 78:2488–2492.

    PubMed  CAS  Google Scholar 

  156. Singer, A., Kruisbeek, A.M., Andrysiak, P.M. 1984. T cell-accessory cell interactions that initiate allospecific cytotoxic T lymphocyte responses: existence of both Ia restricted and Ia-unrestricted cellular interaction pathways. J. Immunol. 132:2199–2209.

    PubMed  CAS  Google Scholar 

  157. Kruisbeek, A.M., Andrysiak, P.M., Singer, A. 1983. Selfrecognition of accessory cell la determinants is required for the in vitro generation of hapten-specific cytotoxic T lymphocyte response. J. Immunol. 131:1650–1655.

    PubMed  CAS  Google Scholar 

  158. Glimcher, L.G., Kim, K.J., Green, I., Paul, W. 1982. Ia antigen bearing tumor cell lines can present protein and alloantigen in a MHC restricted fashion to antigen reactive T cells. J. Exp. Med. 155:445–459.

    PubMed  CAS  Google Scholar 

  159. Wallich, R., Bulbuc, N., Hammerling, G.J., Katzav, S., Segal, S., Feldman, M. 1985. Nature 315:301–305.

    PubMed  CAS  Google Scholar 

  160. Hui, K., Groxveld, F., Festenstein, H. 1984. Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature 311:750–752.

    PubMed  CAS  Google Scholar 

  161. Natali, P.G., Bigotti, A., Nicotra, M.R., Viora, M., Manfredi, D., Ferrone, S. 1984. Distribution of human class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res. 44:4679–4687.

    PubMed  CAS  Google Scholar 

  162. Powell, L.D., Bause, E., Legler, G., Molyneux, R.J., Hart, G.W. 1985. Role of asparagine linked oligosaccharides in the mixed lymphocyte reaction. Effects of Swainsonine and deoxynojirimycin on tumor cell recognition. J. Biol. Chem. in press.

    Google Scholar 

  163. Alexander, S., Hubbard, S.C., Strominger, J.L. 1984. HLA-DR antigens of autologous melanoma and B lymphoblastoid cell lines: differences in glycosylation but not protein structure. J. Immunol. 133:315–320.

    PubMed  CAS  Google Scholar 

  164. Edidin, M. 1983. MHC antigens and non-immune functions. Immunology Today 4:269–270.

    Google Scholar 

Download references

Authors
  1. Robert S. Kerbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas A. Carlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruce E. Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Ronald B. Herberman M.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Kerbel, R.S., Frost, P., Carlow, D.A., Elliott, B.E. (1986). Tumor specific antigens induced by mutagens and DNA hypomethylating agents: implications for the immunobiology of neoplasia. In: Herberman, R.B. (eds) Cancer Immunology: Innovative Approaches to Therapy. Cancer Treatment and Research, vol 27. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2629-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2629-8_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9643-0

  • Online ISBN: 978-1-4613-2629-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation